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BEST-EVIDENCE TOPIC
Do Statin Medications Improve Periodontal Health and/or Outcomes?
A Systematic Review
Eboné Jordan,* Yung-Ting Hsu,* and Jill Bashutski*
Focused Clinical Question:
For adult patients (aged ‡30 years) with chronic periodontitis, does the use of 3-hydroxy-3-methyl-glutaryl coenzyme
A reductase inhibitors (statins) improve periodontal health?
Clinical Scenario:
A 59-year-old female with a history of hyperlipidemia presents for periodontal maintenance care. She has been taking a statin
medication for 4 years, during which time she received comprehensive periodontal therapy, including regenerative surgery in
two quadrants. Post-surgical evaluation revealed substantial gains in clinical attachment and probing depth reduction. Radio-
graphically, significant fill of the intrabony defect was observed. Before treatment, she was very anxious about losing more
teeth and is now curious about the stability of her periodontal treatment. For clinical and radiographic presentation of the
patient, see Figures 1 and 2.
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Background
Chronic periodontitis (CP) is an inflammatory disease
induced by the presence of bacterial pathogens and their
byproducts. The observed tissue and bone breakdown
results from a long-standing inflammatory response
mounted by the immune system of the host.1 Traditionally,
treatment of CP has focused on both non-surgical and
surgical removal of bacterial plaque and calculus by
mechanical means, with the aim to reduce the amount of
local factors that trigger the immune response. More
recently, the approach has shifted from a focus solely on
controlling the exogenous bacterial factors to the goal of
controlling the responses of the host to these triggers and
encouraging regeneration of tissue—in other words, host
modulation.2
Manipulation of the proinflammatory state with phar-
macologic therapies has been investigated.2,3 Many of
the substances (i.e., non-steroidal anti-inflammatory drugs,
statins, bisphosphonates) used are commonly prescribed
drugs that periodontal patients are already taking as a part
of a concurrent systemic disease treatment.2 Examples of
such substances are the 3-hydroxy-3-methyl-glutaryl coen-
zymeA (HMG-CoA) reductase inhibitors, commonly known
as statins. These drugs act as competitive inhibitors of the
enzyme HMG-CoA reductase, thereby preventing a crucial
step in cholesterol synthesis in the liver.4 This effectively
lowers cholesterol and secondarily decreases the incidence
of cardiovascular disease.4
Because inflammation plays a role in cardiovascular dis-
ease, the anti-inflammatory properties of statins have been
studied previously.5 In addition to their cholesterol-lowering
effects, they have pleiotropic features, such as inhibiting the
release of proinflammatorymediators, specifically cytokines
(i.e., tumor necrosis factor-a, chemokines, interleukin [IL]
family) and matrix metalloproteinases (MMPs).6 MMPs
have long been associated with collagen and extracellular
matrix degradation in periodontal disease. There are four
categories ofMMPs—collagenases, gelatinases, stromelysins,
and membrane type—with collagenases (MMP-1, MMP-8,
MMP-13)andgelatinases (MMP-2,MMP-9)beingmostoften
implicated in periodontitis.7,8 Statins have been shown to
reduce the expression of lipopolysaccharide (LPS)-induced
MMP-1, MMP-8, and MMP-9 in monocytes9 and reduce
the expression of MMP-9 in osteoblastic cells.10 LPS is
a well-known component of the cell membrane of Gram-
negative bacteria, which are also the predominant type of
microorganism found in periodontal disease.11Animal stud-
ies demonstrated the effect of statins on alveolar bone loss
and gingival inflammation. In a ligature-induced periodontitis
model in rats, oral simvastatin (SMV) administration reduced
alveolar bone loss and decreased the levels of the proin-
flammatory cytokines MMP-1 and MMP-8, as well as re-
ceptor activator of nuclear factor-kB (RANK) and RANK
ligand.12 In another animal study, both alveolar bone loss
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and osteoclastogenesis were significantly reduced when
SMV was administered to rats with LPS-induced peri-
odontitis.13 These findings in animal studies support previ-
ously published evidence on the effect of statins on improved
bone mineral density and bone formation with statin use in
humans.14 Accordingly, there is biologic plausibility that the
anti-inflammatory and bone formation–promoting actions
of statins could positively affect periodontal treatment out-
comes in humans.
Statins are among the most prescribed and top-selling
drugs in the United States each year.15 This is especially true
among middle-aged adults, in whom systemic diseases,
such as hyperlipidemia, atherosclerosis, and other cardio-
vascular diseases, tend to be most common. CP, too, has
a higher prevalence among adults aged ‡30 years.16 Be-
cause age is a risk indicator for both atherosclerosis and
CP, use of statin therapy could be a potentially convenient
and cost-effective strategy to address both chronic diseases
simultaneously.
Although statins have potentially dangerous adverse ef-
fects, including elevated liver enzymes and rhabdomyolysis,
their incidence is relatively rare.17 This makes the drug an
ideal choice for concomitant therapeutic use for periodontal
disease. With the above purported actions of statins in in-
flammation, it is biologically plausible to expect beneficial
effects of statins in patients with CP. The aim of this review
is to examine the effects of statins, used both systemically
and locally, on treatment outcomes for CP.
Search Strategy
A literature search of PubMed and the Cochrane
Database was performed using the followingMeSH
terms: ((“periodontal diseases”[MeSH Terms] OR
(“periodontal”[All Fields]AND“diseases”[All Fields])
OR “periodontal diseases”[All Fields] OR (“peri-
odontal”[All Fields] AND “disease”[All Fields]) OR
“periodontal disease”[All Fields]) AND (“hydrox-
ymethylglutaryl-coa reductase inhibitors”[Pharma-
cological Action] OR “hydroxymethylglutaryl-coa
reductase inhibitors”[MeSH Terms] OR (“hydroxy-
methylglutaryl-coa”[All Fields]AND“reductase”[All
Fields] AND “inhibitors”[All Fields]) OR “hydroxy-
methylglutaryl-coa reductase inhibitors”[All Fields]
OR “statins”[All Fields])) AND (“1980”[PDAT]:
“3,000”[PDAT])
Search Outcome
The literature search yielded 49 papers related to the search
topic. Forty-six full-text articleswere reviewed. Three papers
were written in languages other than English. Of the 46 re-
viewed papers, four randomized clinical trials (RCTs)18-21
and seven cross-sectional or cohort studies22-28 were selected
for inclusion (Tables 1 and 2). The remaining papers were
eliminated because of lack of human participants or lack
of direct evaluation of periodontal conditions.
Discussion
This review of the literature revealed a paucity of clinically
controlled trials and a noticeable heterogeneity in design
among cross-sectional and cohort studies regarding the
FIGURE 1 Initial clinical presentation.
FIGURE 2a Lower right quadrant before comprehensive periodontal
treatment with concurrent systemic statin administration. 2b Lower right
quadrant 2 years after comprehensive periodontal treatment with concurrent
systemic statin administration.
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association of HMG-CoA reductase inhibitors and peri-
odontal disease. For the clinical trials, statin use, both sys-
temically and locally, was associated with an improvement
in periodontal parameters.18-20 One of the trials18 showed
a statistically significant improvement on tooth mobility
and radiographic bone level with the once-daily use of sys-
temically administered atorvastatin (ATV).However, these
results should be interpreted with caution because of the
short follow-up period (3 months) and atypical method
of assessing tooth mobility. Conversely, the radiographic
bone level can be seen as statistically and, presumably, clin-
ically significant, with the control group losing bone height
(crest of alveolar bone–cemento-enamel junction [CAB-
CEJ] at baseline [BL], 2.71 – 1.43 mm versus 3 months,
2.80 – 1.52 mm) and the test (ATV) group gaining bone
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loss, dental mobility38 [0 ¼
absent or 1 ¼ present;
recorded as percentage of
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SMV in situ gel (test) at
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defect fill for the test
group versus the control
group.
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2.10 – 1.14 mm). The most significant improvement in
common periodontal parameters was seen with the use of
a locally delivered form of SMV, used as an adjunct to
non-surgical periodontal therapy.19,20 Probing depth (PD),
clinical attachment level (CAL), and inflammation (as mea-
sured by a modified sulcus bleeding index [mSBI]) all ex-
hibited statistically and, presumably, clinically significant
improvement over controls for both a systemically healthy19
and a diabetic20 participant group; on average, more than
twice the reduction in PD and CAL was seen in the SMV
group (for both studies) when compared with the placebo
group for all time points studied.19,20 Therapeutic treatment
outcomes may be improved when administering a statin lo-
cally compared with systemically. The application of a statin
on a localized level may eliminate the resultant dose decrease
seen at bone sites after the first-pass liver metabolism.29 Fur-
thermore, in two of the above trials,19,20 gingival crevicular
fluid (GCF) analysis of the treatment site demonstrated that
the delivery vehicle allowed for an extended release of the
drug for up to 30 days.
With regard to the cross-sectional and cohort studies,
there was only a weak positive correlation of statins to im-
proved periodontal parameters. Many of the studies
showed an association with statin use and fewer periodon-
tal pockets (defined as PDs of 3 to 4mm).24,25,27 Parameters
such as PD, CAL, and bleeding on probing (BOP) can serve
as surrogate endpoints for the actual true endpoint of tooth
loss. Interestingly, however, the retrospective studies eval-
uating the impact of statin therapy on tooth loss showed
either no reduction in tooth loss23 or weak associationwith
tooth loss reduction22—one in which a reduction in tooth
loss was related to time of periodontal disease diagnosis
and time of statinmedication being dispensed. For the study
that did show a slight reduction in tooth loss,22 it was inter-
esting to note that this relationshipwas not found to be dose
dependent. One must regard the results of this retrospective
cohort study, inwhich only insurance information was eval-
uated, with caution. Although the authors tried to control
for the potential confounding factor of extractions attribut-
able to non-periodontally related issues (i.e., consideration
of total caries-related procedures), the lack of information re-
garding the reason for extraction does not permit a true un-
derstanding of periodontal tooth loss in statin users, because
non-usersmay have had similar tooth loss rates that were un-
related to periodontal disease. Additionally, studies suggest
that well-maintained, compliant patient populations may
exhibit higher rates of tooth loss than poorly maintained
populations—a trend that may provide insight into the lack
of difference seen between the statin group and others.
Statins exert their inflammation-modulating effects on
many levels, including the reduction of C-reactive protein
levels,30 blockage of the effects of proinflammatory cyto-
kine IL-6,31 and suppression of tissue-degradativeMMPs.9
Animal studies demonstrated the positive effects of statins
on bone metabolism, specifically with regard to stimulation
of bonemorphogenetic protein-232 and increased expression
of vascular endothelial growth factor in osteoblasts.33 Seto
et al.34 showed increased bone formation in rat calvaria after
the topical administration of SMV, revealing its ability to
maintain high osteoblastic function. In addition, itwas dem-
onstrated in another animal study that the application of
SMV, ina cyclosporineA (CsA)–inducedperiodontal disease
model, counteracted the deleterious effects of the CsA on
bone turnover.35
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PI ¼ plaque index; GR ¼ gingival recession; SRP ¼ scaling and root planing; OHI ¼ oral hygiene instruction; LDL ¼ low-density lipoprotein; IBD ¼ intrabony defect;
FDG/PET-CT ¼ 2-18F-fluoro-2-deoxy-D-glucose/positron emission tomography-computed tomography.
B E S T - E V I D E N C E T O P I C
Jordan, Hsu, Bashutski Clinical Advances in Periodontics, Vol. 4, No. 3, August 2014 197
Based on the results presented herein, there is promising,
albeit preliminary, information regarding the benefits of
statin use on periodontal treatment outcomes. The current
widespread use of these medications in the adult popula-
tion coupled with the increased prevalence of periodontal
disease in this same population makes their use in peri-
odontal therapy both practical and economical. The early
evidence of the prospective RCTs are promising, especially
given the benefit of a locally delivered method of adminis-
tration that is associatedwith fewer side effects anda reduced
need for patient compliance. However, the conclusions are
a reflection of a relatively small sample size and therefore
need to be demonstrated in the larger population as awhole.
Therefore, future endeavorsmight include large-scale, cross-
sectional studies that correlate statin use with overall peri-
odontal condition (i.e., National Health and Nutrition
Examination Survey III data mining); such an analysis
would provide a large enough sample size to control for
confounders. With that correlation established, research
should then be aimed at evaluating the benefit of HMG-
CoA reductase inhibitors on periodontal disease through
well-controlled, largely powered, prospective clinical trials
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N ¼ 3,156 dentate
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cluster sampling in the
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generalized CP (AL of
3 to 5 mm in >30%
of sites); group 1
(n ¼ 15), 20 mg/d
ATV; group 2 (n ¼ 15),
control
Cross-sectional The clinical parameters
recorded were PI, GI,
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GCF samples analyzed for
IL-1b using commercially
available ELISA. GCF IL-1b levels in
patients with CP
on statin medication
were lower than patients
with CP not taking statin
medication.











HMO ¼ health maintenance organization; AL ¼ attachment loss; PI ¼ plaque index; PIBI ¼ periodontal inflammatory burden index; LDL ¼ low-density lipoprotein;
HDL ¼ high-density lipoprotein; GI ¼ gingival index; ELISA ¼ enzyme-linked immunosorbent assay.
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that showcase the improvement in clinical parameters in
patients with periodontal disease. n
Clinical Bottom Line
In adult patients (aged ‡30 years) with CP, the use of statins
may show a positive effect on periodontal status (i.e., tooth
loss, inflammation). Additionally, in patients undergoing
non-surgical periodontal therapy, concomitant administra-
tion of statins may help improve periodontal outcomes.
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